These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 25937299)

  • 21. Blockade of the ERK or PI3K-Akt signaling pathway enhances the cytotoxicity of histone deacetylase inhibitors in tumor cells resistant to gefitinib or imatinib.
    Ozaki K; Kosugi M; Baba N; Fujio K; Sakamoto T; Kimura S; Tanimura S; Kohno M
    Biochem Biophys Res Commun; 2010 Jan; 391(4):1610-5. PubMed ID: 20026060
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A synthetic naringenin derivative, 5-hydroxy-7,4'-diacetyloxyflavanone-N-phenyl hydrazone (N101-43), induces apoptosis through up-regulation of Fas/FasL expression and inhibition of PI3K/Akt signaling pathways in non-small-cell lung cancer cells.
    Bak Y; Kim H; Kang JW; Lee DH; Kim MS; Park YS; Kim JH; Jung KY; Lim Y; Hong J; Yoon DY
    J Agric Food Chem; 2011 Sep; 59(18):10286-97. PubMed ID: 21877710
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Curcumin inhibits cell proliferation and induces apoptosis of human non-small cell lung cancer cells through the upregulation of miR-192-5p and suppression of PI3K/Akt signaling pathway.
    Jin H; Qiao F; Wang Y; Xu Y; Shang Y
    Oncol Rep; 2015 Nov; 34(5):2782-9. PubMed ID: 26351877
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibition of autophagy enhances effects of PF-04691502 on apoptosis and DNA damage of lung cancer cells.
    Fei HR; Tian H; Zhou XL; Yang MF; Sun BL; Yang XY; Jiao P; Wang FZ
    Int J Biochem Cell Biol; 2016 Sep; 78():52-62. PubMed ID: 27378731
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Growth inhibition of combined pathway inhibitors on KRAS mutated non-small cell lung cancer cell line].
    Li ZW; Yang ZL; Feng HL; Bian XC; Liu YY; Liu YQ
    Zhonghua Bing Li Xue Za Zhi; 2013 May; 42(5):330-5. PubMed ID: 24004591
    [TBL] [Abstract][Full Text] [Related]  

  • 26. TMEM100 induces cell death in non‑small cell lung cancer via the activation of autophagy and apoptosis.
    He Q; Dong Y; Zhu Y; Ding Z; Zhang X; Wang Z; Ai R; He Y
    Oncol Rep; 2021 May; 45(5):. PubMed ID: 34184748
    [TBL] [Abstract][Full Text] [Related]  

  • 27. High level of AKT activity is associated with resistance to MEK inhibitor AZD6244 (ARRY-142886).
    Meng J; Peng H; Dai B; Guo W; Wang L; Ji L; Minna JD; Chresta CM; Smith PD; Fang B; Roth JA
    Cancer Biol Ther; 2009 Nov; 8(21):2073-80. PubMed ID: 19783898
    [TBL] [Abstract][Full Text] [Related]  

  • 28.
    Dolgikh N; Hugle M; Vogler M; Fulda S
    Cancer Res; 2018 Apr; 78(8):2000-2013. PubMed ID: 29437705
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Metformin and buparlisib synergistically induce apoptosis of non-small lung cancer (NSCLC) cells via Akt/FoxO3a/Puma axis.
    Shanshan W; Hongying M; Jingjing F; Rui Y
    Toxicol In Vitro; 2024 May; 97():105801. PubMed ID: 38479708
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Generation and characterization of MEK and ERK inhibitors- resistant non-small-cells-lung-cancer (NSCLC) cells.
    Iezzi A; Caiola E; Scagliotti A; Broggini M
    BMC Cancer; 2018 Oct; 18(1):1028. PubMed ID: 30352565
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rational development of synergistic combinations of chemotherapy and molecular targeted agents for colorectal cancer treatment.
    Tosi D; Pérez-Gracia E; Atis S; Vié N; Combès E; Gabanou M; Larbouret C; Jarlier M; Mollevi C; Torro A; Del Rio M; Martineau P; Gongora C
    BMC Cancer; 2018 Aug; 18(1):812. PubMed ID: 30103709
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety and Efficacy of Buparlisib (BKM120) in Patients with PI3K Pathway-Activated Non-Small Cell Lung Cancer: Results from the Phase II BASALT-1 Study.
    Vansteenkiste JF; Canon JL; De Braud F; Grossi F; De Pas T; Gray JE; Su WC; Felip E; Yoshioka H; Gridelli C; Dy GK; Thongprasert S; Reck M; Aimone P; Vidam GA; Roussou P; Wang YA; Di Tomaso E; Soria JC
    J Thorac Oncol; 2015 Sep; 10(9):1319-1327. PubMed ID: 26098748
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treating non-small cell lung cancer by targeting the PI3K signaling pathway.
    Jiang L; Zhang J; Xu Y; Xu H; Wang M
    Chin Med J (Engl); 2022 Jun; 135(11):1272-1284. PubMed ID: 35830272
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dual Targeting of Autophagy and MEK in KRAS Mutant Cancer.
    Zhao H; Zheng B
    Trends Cancer; 2019 Jun; 5(6):327-329. PubMed ID: 31208693
    [TBL] [Abstract][Full Text] [Related]  

  • 35. PSMG2-controlled proteasome-autophagy balance mediates the tolerance for MEK-targeted therapy in triple-negative breast cancer.
    Wang X; Yu J; Liu X; Luo D; Li Y; Song L; Jiang X; Yin X; Wang Y; Chai L; Luo T; Jing J; Shi H
    Cell Rep Med; 2022 Sep; 3(9):100741. PubMed ID: 36099919
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A Novel PDK1/MEK Dual Inhibitor Induces Cytoprotective Autophagy via the PDK1/Akt Signaling Pathway in Non-Small Cell Lung Cancer.
    Liu R; Chen Z; Hu G; Yu Z; Li Q; Liu D; Li L; Liu Z
    Pharmaceuticals (Basel); 2023 Feb; 16(2):. PubMed ID: 37259393
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combination Treatment With Inhibitors of ERK and Autophagy Enhances Antitumor Activity of Betulinic Acid in Non-small-Cell Lung Cancer
    Sun CY; Cao D; Ren QN; Zhang SS; Zhou NN; Mai SJ; Feng B; Wang HY
    Front Pharmacol; 2021; 12():684243. PubMed ID: 34267658
    [TBL] [Abstract][Full Text] [Related]  

  • 38. DIRAS3: An Imprinted Tumor Suppressor Gene that Regulates RAS and PI3K-driven Cancer Growth, Motility, Autophagy, and Tumor Dormancy.
    Bildik G; Liang X; Sutton MN; Bast RC; Lu Z
    Mol Cancer Ther; 2022 Jan; 21(1):25-37. PubMed ID: 34667114
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pazopanib diminishes non-small cell lung cancer (NSCLC) growth and metastases in vivo.
    Zhao H; Yang F; Shen W; Wang Y; Li X; You J; Zhou Q
    Thorac Cancer; 2015 Mar; 6(2):133-40. PubMed ID: 26273349
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Unraveling the prevalence of various signalling pathways in non-small-cell lung cancer: a review.
    Nair AS; Jayan AP; Anandu KR; Saiprabha VN; Pappachen LK
    Mol Cell Biochem; 2023 Dec; 478(12):2875-2890. PubMed ID: 37014561
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.